Galaxy Digital in Roughly $100 Million Stock Offering
By Robb M. Stewart
Galaxy Digital Holdings is seeking to raise roughly $100 million via an equity raising.
The digital asset and blockchain company, which has earmarked the proceeds of the bought deal public offering for working capital and general corporate purposes, said Tuesday it entered into an agreement with Canaccord Genuity that will see the underwriter buy 9.75 million shares at 14 Canadian dollars ($10.31) each, for gross proceeds of C$136.5 million.
Certain shareholders, including Galaxy Group Investments, granted the underwriter an option to buy up to an additional 1.5 million shares that they hold at the same offering price during a 30-day period after the offering closes. That could see proceeds for these shareholders of up to roughly $15 million.
The offering is set to close on or about Friday, Galaxy said.
Late last month, the company recorded a swing to fourth-quarter net income of $301.5 million from a year-earlier loss of $288.8 million as fee revenue and lending and staking revenue each more than doubled.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
April 09, 2024 07:43 ET (11:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks